Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC.FENC · Entity 5601 | Director | June 10, 2026 | June 10, 2026 |
| TENAX THERAPEUTICS, INC.TENX · Entity 979 | Director | May 01, 2019 | June 15, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FENNEC PHARMACEUTICALS INC.
Report date June 10, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $8.70 · Expires 2036-06-10 | Direct | 200,000 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 20,000 · Balance 200,000 F1: On June 10, 2026, Chris Rallis was granted a non-qualified stock option to purchase 20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan. F2: The option is 100% vested on date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 10, 2026, Chris Rallis was granted a non-qualified stock option to purchase 20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan.
F2: The option is 100% vested on date of grant.
TENAX THERAPEUTICS, INC.
Report date May 01, 2019 · Filed June 15, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.66 · Expires 2030-05-01 | Direct | 500 |
Reported balance
After 2020-05-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-01 · Grant · Acquired 500 · Balance 500 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.72 · Expires 2029-05-01 | Direct | 500 |
Reported balance
After 2019-05-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-05-01 · Grant · Acquired 500 · Balance 500 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2023 Filed Mar 3, 2023 22:35 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares | 4,166 | $2.40 | $9,998.40 |
DisclosureSEC source: 0001415889-23-004182 · form4-03032023_100359.xml · nonDerivative · entry 1 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,184 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents options granted April 3, 2013, with a $2.40 USD strike price and expiration of April 3, 2023. Read SEC document |
| November 17, 2022 Filed Nov 17, 2022 21:09 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon Shares | 333 | $7.99 | $2,660.67 |
DisclosureSEC source: 0001415889-22-011492 · form4-11172022_091140.xml · nonDerivative · entry 1 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,018 F1 · security: Represents shares sold pursuant to a 10b5-1 plan on November 17, 2022. Read SEC document |
| October 20, 2022 Filed Oct 20, 2022 20:15 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Tax withholdingCommon Shares | 2,068 | $8.26 | $17,081.68 |
DisclosureSEC source: 0001415889-22-010738 · form4-10202022_011051.xml · nonDerivative · entry 2 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,351 F2 · security: Represents shares automatically sold pursuant to a 10b5-1 plan to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the exercise of 4,762 shares from an November 11, 2012 grant. Read SEC document |
| October 20, 2022 Filed Oct 20, 2022 20:15 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares | 4,762 | $1.05 | $5,000.10 |
DisclosureSEC source: 0001415889-22-010738 · form4-10202022_011051.xml · nonDerivative · entry 1 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents options granted on November 11, 2012, with a $1.05 USD strike price and an expiration of November 11, 2022. Read SEC document |
| July 18, 2022 Filed Jul 18, 2022 22:00 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Tax withholdingCommon Shares | 4,379 | $6.70 | $29,339.30 |
DisclosureSEC source: 0001104659-22-080585 · tm2221334-1_4seq1.xml · nonDerivative · entry 2 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,657 F2 · security: Represents shares automatically sold pursuant to a 10b5-1 plan to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the exercise of 11,111 shares from an August 17, 2012 grant. Read SEC document |
| July 18, 2022 Filed Jul 18, 2022 22:00 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares | 11,111 | $0.45 | $4,999.95 |
DisclosureSEC source: 0001104659-22-080585 · tm2221334-1_4seq1.xml · nonDerivative · entry 1 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,036 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents options granted on August 17, 2012, with a $0.45 USD strike price and an expiration of August 17, 2022. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 13:26 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $5.59 | $0.00 |
DisclosureSEC source: 0001104659-22-071690 · tm2218610-5_4seq1.xml · derivative · entry 1 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2032-06-14 F1 · security: On June 14, 2022, Chris Rallis was granted a non-statutory stock option to purchase 20,000 shares of the Issuer's common shares pursuant to the Issuer's Equity Incentive Plan. F2 · derivative.exercise_date: The option is 100% vested on the date of grant. Read SEC document |
| March 08, 2022 Filed Mar 8, 2022 13:24 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares | 9,259 | $0.54 | $4,999.86 |
DisclosureSEC source: 0001104659-22-031286 · tm228629-1_4seq1.xml · nonDerivative · entry 2 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,925 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Represents options granted on May 17, 2012, with a $0.54 USD strike price and an expiration of May17, 2022. Read SEC document |
| March 08, 2022 Filed Mar 8, 2022 13:24 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares | 8,333 | $0.60 | $4,999.80 |
DisclosureSEC source: 0001104659-22-031286 · tm228629-1_4seq1.xml · nonDerivative · entry 1 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents options granted on April 4, 2012, with a $0.60 USD strike price and an expiration of April 4, 2022. Read SEC document |
| October 21, 2021 Filed Oct 21, 2021 19:40 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares | 3,333 | $1.50 | $4,999.50 |
DisclosureSEC source: 0001104659-21-128430 · tm2130788-1_4seq1.xml · nonDerivative · entry 1 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents options granted on November 18, 2011, with a $1.50 USD strike price and an expiration of November 18, 2021. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 19:44 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $7.52 | $0.00 |
DisclosureSEC source: 0001104659-21-087517 · tm2121155-5_4seq1.xml · derivative · entry 1 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2031-06-29 F1 · security: On June 29, 2021, Chris Rallis was granted a non-statutory stock option to purchase 20,000 shares of the Issuer's common shares pursuant to the Issuer's Equity Incentive Plan. F2 · derivative.exercise_date: The option is 100% vested on the date of grant. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 19:18 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $6.17 | $0.00 |
DisclosureSEC source: 0001104659-20-095451 · tm2027709d5_4.xml · derivative · entry 1 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2030-08-13 F1 · security: On August 13, 2020, Chris Rallis was granted a non-statutory stock option to purchase 20,000 shares of the Issuer's common shares pursuant to the Issuer's Equity Incentive Plan. F2 · derivative.exercise_date: The option is 100% vested on the date of grant. Read SEC document |
| May 01, 2020 Filed Jun 15, 2020 20:30 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock Option (right to buy) · Derivative | 500 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001654954-20-006645 · section16.xml · derivative · entry 1 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Underlying: Common Stock · 500 shares Expires 2030-05-01 Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 00:34 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.26 | $0.00 |
DisclosureSEC source: 0001144204-19-031566 · tv523895_4.xml · derivative · entry 1 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2029-06-18 F1 · security: On June 18, 2019, Chris Rallis was granted an incentive stock option to purchase 20,000 shares of the Issuer's common shares pursuant to the Issuer's Amended and Restated Stock Option Plan. F2 · derivative.exercise_date: The option is 100% vested on the date of grant. Read SEC document |
| May 01, 2019 Filed Jun 15, 2020 20:30 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock Option (right to buy) · Derivative | 500 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001654954-20-006645 · section16.xml · derivative · entry 2 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Underlying: Common Stock · 500 shares Expires 2029-05-01 Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 14:40 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $10.93 | $0.00 |
DisclosureSEC source: 0001144204-18-033676 · tv496269_4.xml · derivative · entry 1 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2025-06-08 F1 · security: On June 8, 2018, Chris A. Rallis was granted an incentive stock option to purchase 20,000 common shares of the Issuer pursuant to the Issuer's Amended and Restated Stock Option Plan. The option is 100% vested on the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.